Last
Update:
July 30, 2011
Perinatal Journal Data are integrated with Perinatal Conference Data in
the Perinatal Data Page.
Pediatric Journal Data are integrated with Pediatric Conference Data in
the Pediatric Data Page
 Documents identified with this icon
are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader.
- POSTER
Efavirenz plasma concentration in HIV-infected patients treated for tuberculosis
by a rifampicin-based regimen in the camelia clinical trial (ANRS 1295/12160 -
CIPRA KH001/10425)
L. Borand, D. Laureillard, M. Chou, et al
Poster
Abstract
A comparative analysis
of risk factors associated with efavirenz, darunavir/ritonavir,
lopinavir/ritonavir,
atazanavir/ritonavir and
renal impairment
N. Rockwood, M. Nelson, S. Mandalia, B. Gazzard
Abstract
Predictors of
nevirapine and efavirenz toxicity in HIV-infected patients: updated analysis
from the TREAT Asia HIV Observational Database (TAHOD)
L. Lee, P.-L. Lim, P. Fahey, et al
Abstract
Quantification of
efavirenz and efavirenz metabolites in human plasma using LC/MS: correlation to
neuropsychatric symptoms
T.M. Binz, A. Gras, M. Vaillant, et al
Abstract
Identification of
HIV-infected Ghanaian patients with low or high efavirenz plasma mid-dose
concentrations
A. Kwara, H. Yang, M. Lartey, et al
Abstract
HIV/AIDS patients
display lower efavirenz relative bioavailability compared to healthy volunteers
J.K. Mukonzo,,S. Nanzigu, R. Dinko. et al
Abstract
|
EFV Pharmacokinetics during the Third Trimester of Pregnancy and Postpartum
T Cressey, A Stek, E Capparelli,
PDF Poster
Abstract
POSTER
Comparison of Durability and Patient Survival
between NVP-based and EFV-based First-line ART Regimens in China’s
National Free
ART Program
Yao Zhang, Y Ma, R Zhang, et al
PDF Poster
Abstract
POSTER
Adipogenic Gene Variants Are Associated with Lipid Changes in HIV+
Adults on EFV- and LPV-based Regimens
S Pushpakom, T Mahungu, T Farragher, et al
PDF Poster
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and
Safety of EFV with either Co-formulated 3TC/ZDV or FTC/TDF for Initial Treatment
of HIV-1-infected Men
and Women in Diverse Multinational Settings: ACTG PEARLS
Study
T Campbell, L Smeaton, N Kumarasamy,
et al
Abstract
Neurologic and
Psychiatric Safety Profile of TMC278 Compared with EFV in Treatment-naive HIV-1+
Patients:
ECHO and THRIVE Trials at 48 Weeks
A Mills, A Antinori, B Clotet, et
al
Abstract
Central Fat
Accumulation in ART-naïve Subjects Randomized to ABC/3TC or TDF/FTC with ATV/r
or EFV:
ACTG A5224s, a Substudy of ACTG A5202
G McComsey, D Kitch, P Sax, et al
Abstract
Whole Genome
Association Study of Viral Failure with EFV- and/or ABC-containing Regimens in
ACTG Studies
P McLaren, H Ribaudo, E Daar, et al
Abstract
Lipid Profiles
of TMC278 and EFV in Treatment-naïve HIV-1+ Patients: Pooled Week-48
Data from the Randomized
Double-blind Phase III ECHO and THRIVE Trials
J Arribas, J Andrade-Villanueva, N
Bellos, et al
Abstract
|
11th Int. Workshop on Clinical
Pharmacology of
HIV Therapy |
RESENTATION
Investigation of the association of CYP2B6 haplotypes with efavirenz plasma
concentrations
in a Chilean HIV cohort.
D Carr, CJL La Porte, D Egan , et al
2-Year Evolution of Triglycerides and
Cholesterol in Thai HIV-1-infected Children Receiving
First-line NVP or Efavirenz EFV-based Regimen
S Kanjanavanit, R Hansudewechakul, S Kim,
et al
PDF Poster
Abstract
POSTER
A One-pill, Once-daily Fixed-dose Combination of Efavirenz,
Emtricitabine, and
Tenofovir Disoproxil Fumarate Regimen Is Associated with Higher Unannounced
Pill Count Adherence than Non-one-pill, Once-daily Regimens
D Bangsbe, K Ragland, A
Monk, et al
1
PDF Poster
Abstract
POSTER
Genotypic Resistance at Viral Rebound in Antiretroviral-Naive Subjects
Randomized to
Receive Lopinavir/Ritonavir (LPV/r) or Efavirenz (EFV)-Based Regimens in South
Africa -
A Substudy of the Phidisa II Trial
J Dlamini, Z H, L Morris, et al
PDF Poster
Abstract
POSTER
Metabolic Profiles and Body Composition Changes in Treatment-Naive HIV-Infected
Patients
Treated with Raltegravir 400 mg Twice-daily vs Efavirenz 600 mg Each bedtime
Combination
Therapy: 96-Week Follow-Up
E DeJesus, C Cohe, J Lennox,
et al
PDF
Poster
Abstract
POSTER
Pharmacokinetic Interactions between the Hormonal Emergency Contraception,
Levonorgestrel,
and Efavirenz
M Carten, J Kiser, A Kwara, et al
PDF Poster
Abstract
POSTER
Pharmacokinetics of Efavirenz Dosed According to the WHO Weight-bands in
Children in Uganda
S Bakeera-Kitaka, E Natukunda, L Kendall, et al
PDF Poster
Abstract
Pregnancy,
Efavirenz, and Birth Outcomes in Johannesburg
D Westreich, D Rubel, P MacDonald,
et al
Abstract
|
|
-
POSTER
Therapeutic drug monitoring (TDM) enables efavirenz dose reduction in
virologically-controlled
patients
A. Calmy, A. Fayet, M. Cavassini, et al
PDF Poster
Abstract
-
A
WEEK-IN-REVIEW-FEATURED REPORT
POSTER
Frequency of
lipodystrophy in a large observational cohort using either LPV/r or EFV in
combination with
contemporary nucleoside analogues
J. van Lunzen, R. Pauli, A. Trein, et al
PDF Poster
Abstract
-
POSTER
T-cell marker
activation, and mitochondrial membrane integrity after exposure to lopinavir,
ritonavir or
efavirenz on HIV-negative CD4+ lymphocytes
J. Scott, S. O'Barr, T. Sparrow, et al
PDF Poster
Abstract
-
POSTER
Efavirenz conceptions in Soweto, South Africa
F. Laher, J. Forrest, L. Mohapi, G. Gray
PDF Poster
Abstract
-
Preliminary safety
results of co-administration of nevirapine (NVP) or efavirenz (EFV), and
rifampicin (RMP) in HIV-tuberculosis (TB) co-infected patients in Maputo
(Mozambique):
CARINEMO-ANRS 12146 Trial
N.B. Bhatt, E. Baudin, I.V. Jani, et al
Abstract
-
Analysis of the
mean increase in CD4 cell counts and viral load decrease between different
subtypes C,
CRF31_BC, B and F after initial antiretroviral therapy in a Porto Alegre HIV
clinic,
southern of Brazil
C. Nunes, C. Dias, I. Lamego, L. Brigido
Abstract
-
The FOTO study: The
48 week extension to assess durability of the strategy of taking efavirenz,
tenofovir and emtricitabine Five days On, Two days Off (FOTO) each week in
virologically
suppressed patients
C. Cohen, A. Colson, G. Pierone, et al
Abstract
|
No Effect of Prior Nevirapine Use on 6-Month
Virologic and CD4 Responses after Commencement of
Efavirenz-based
Combination ART in a Cohort of South African HIV+ Females
J Dlamini, A Pau, D Follmann, et al
PDF Poster
Abstract
POSTER
96-Week Effects of Suppressive
Efavirenz-containing ART, Abacavir, and Sex on High-sensitivity C-reactive
Protein: ACTG A5095
C Shikuma E Zheng, H Ribaudo, et al
PDF Poster
Abstract
POSTER
Age-related Pharmacokinetics of
Efavirenz Solution
E Capparelli M Rochon-Duck, B Robbins, et al
PDF Poster
Abstract
POSTER
No Effect of Prior Nevirapine Use on 6-Month Virologic and CD4 Responses after
Commencement of
Efavirenz-based Combination ART in a Cohort of South African HIV+
Females
J Dlamini, A Pau, D Follmann, et al
PDF Poster
Abstract
POSTER
Efavirenz and Emtricitabine
Concentrations Consistently Exceed Wild-type IC50 in Cerebrospinal
Fluid:
CHARTER Findings
B Best, S Letendre, E Capparelli, et al
PDF Poster
Abstract
POSTER
Efavirenz Causes Accumulation of
Intracellular Lipids in Hepatic Cells
A Blas-García, D Ballesteros, D Monleón, et al
PDF Poster
Abstract
CONFERENCE POSTER
Phidisa II: A Randomized 2x2
Factorial Trial Comparing Initial Therapy of Efavirenz with Lopinavir/Ritonavir
and
Zidovudine + Didanosine with Stavudine + Lamivudine in Treatment-naïve
HIV-infected Persons with < 200 CD4+
Cells/mm3 or a Prior AIDS Diagnosis
A Ratsela, M Polis, and the Phidisa II Study Group
PDF Poster
Abstract
Are
Recommended Dosages of Efavirenz Optimal in Young Children? ANRS 12103
D Hirt, S Urien, M Olivier, et al
Efavirenz
Plasma Concentrations and the Association with CYP2B6-516 T Polymorphism in
HIV-infected Thai Children
T Puthanakit, P
Tanpaiboon, L Aurpibul, et al
Concentrations
of Efavirenz in Hair Are Strongly Correlated with Virologic Response
M Gandhi, N Ameli, P Bacchetti. et
al
Analyses of
Efavirenz Metabolism in vivo in Genetically Characterized Individuals
J Di Iulio, M Rotger, A Fayet, et
al
Efavirenz
Increases MRP1 Efflux Transporter Function while Darunavir/Ritonavir Inhibits
MRP1 Expression in
Healthy
Volunteers
L Lee, G Soon, P Shen, et al
The Genetic
Determinants of High-density Lipoprotein Cholesterol Changes in HIV-1-infected
Adults on
Efavirenz-based Regimens
T Mahungu, D Nair, C Smith, et al
Ninth International Congress on Drug Therapy in HIV Infection
|
PDF Poster
Differences in CD4 count
increases in veterans starting antiretroviral therapy with lopinavir/ritonavir
or efavirenz
Bedimo RJ, Drechsler H, Holodniy M, et al
Abstract
The
FOTO study: 24-week results support the safety of a 2-day break on
efavirenz-based antiretroviral therapy
C Cohen, A Colson, G Pierone,
et al
PDF Abstract
Impact
of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as
tablets and capsules
in
African patients
C Kityo, AS Walker, F Lutwana,
et al
PDF Abstract
Efavirenz
induces alterations in lipid metabolism through AMPK activation
Blas-García A, Ballesteros D, Monleón D, et al
Abstract
Clinical concentrations of efavirenz (EFV) reduce cellular
proliferation and viability in several human cell lines
Apostolova N, Blas-García A, Ballesteros D, et al
Abstract
Efavirenz
and rifampicin in the South African context: is there a need to
dose increase efavirenz with concurrent
rifampicin
therapy?
Orrell C, Cohen K, Ive P, et al
Abstract
XVII
International AIDS Conference
|
B. Purandare, V. Purandare, D. Padhya, et al
Abstract
Quantifying the risks and benefits of efavirenz (EFV) use in HIV-infected
women of childbearing age in the US
H. Hsu, C. Rydzak, K. Cotich, et al
Abstract
A low dose of efavirenz provides adequate efavirenz plasma concentrations
in Thai HIV-1 infected adults
A.
Avihingsanon, J. Van der Lug, M. Gorowara,
et al
Abstract
Efavirenz in pregnancy: maternal characteristics of women who become
pregnant on EFV-containing regimen
and neonatal effects
M.I.
Gonzalez-Tome, M. Fernandez-Ibieta J. Ramos Amador
et al
Abstract
Efficacy of subsequent efavirenz-based regimen in HIV-infected patients
with preceding discontinuation of nevirapine
W. Manosuthi, S. Chimsuntorn, S. Sungkanuparph
Effect of intermittent versus continuous exposure to efavirenz on
depressive symptoms in HIV-infected adults
in West Africa (Trivacan ANRS 1269 trial)
F. Marcellin, R. Moh, M.P. Carrieri, et al
Abstract
Plasma efavirenz (EFV) level and CYP450 2B6 genotype in HIV patients on
HAART in Southern China
S.T. Liu, K.W. To, R.C.Y. Chan, et al
POWERPOINT POSTER PRESENTATION
A prospective,
randomized, open label trial of efavirenz versus lopinavir/ritonavir based HAART
among antiretroviral
therapy naïve, HIV infected individuals presenting for care with CD4 cell counts
<200/mm3 in Mexico
J Sierra Madre
Poster Presentation
POWERPOINT POSTER PRESENTATION
Once-a-day pediatric
HAART with DDI+3TC+EFV in Burkina Faso - a phase II Trial (ANRS 12103 trial)
P Msellati
Poster Presentation
9th Int. Workshop on Clinical
Pharmacology of HIV Therapy
|
CONFERENCE PDF PRESENTATION
Factors influencing efavirenz and nevirapine plasma concentration: effect of
ethnicity, weight and comedication.
Stoehr W, Back D, Dunn D, et al
Presentation
-
A WEEK IN REVIEW
FEATURED REPORT
Outcomes of Abacavir- and Efavirenz-based HAART: Comparison of ACTG
5095 Trial Results with
Observational Cohort Studies
M Mugavero, M May, H Ribaudo, et al
Abstract
-
POSTER
Efavirenz Induces CYP450 2B6 Activity as Measured by Bupropion
Hydroxylation in Healthy Subjects
S Robertson, F
Maldarelli, V Natarajan, et al
PDF
Poster
Abstract
-
POSTER
Influence of NRTI Choice and Efavirenz vs Lopinavir Treatment Options on
Lipoatrophy-associated
Adipose Tissue Toxicity: A Longitudinal Study
E Hammond, B McKinnon, C Pace, et al
PDF
Poster
Abstract
-
Presence of Minor Populations of Y181C Mutants Detected by Allele-specific
PCRand Risk of
Efavirenz Failure in Treatment-naïve Patients: Results of an ACTG 5095
Case-cohort Study
R Paredes, C Lalama, H Ribaudo, et al
Abstract
-
Genetic
Variation in Accessory Metabolic Pathways Is Associated with Extreme Efavirenz
Exposure
in
Individuals with Impaired CYP2B6 Function
J di Lulio, M Rotger, R Lubomirov, et al
Abstract
-
NNRTI,
Efavirenz and Nevirapine, Induce Leukocyte-Endothelial Cell Interactions in
the Microvasculature
M Andrade, F Baixauli, A Blas-Garcia, et al
Abstract
-
Intracellular Accumulation of Tenofovir and Emtricitabine in vitro
Highlight the Inhibitor Role of
Efavirenz for Multridrug Resistance-Associated Protein 1, MRP1
L Bousquet, A Pruvost, N Didier, et al
Abstract
-
Acute
Inhibition of Mitochondrial Function by Efavirenz Induces Changes in Cellular
Lipid Metabolism
A Blas-Garcia, M Rocha, F
Baixauli, et al
Abstract
-
POSTER
Fasted Lipid Changes
after Administration of Maraviroc or Efavirenz in Combination with
Zidovudine
and Lamivudine for 48 weeks to Treatment-naïve HIV-infected
Patients
E DeJesus, S Walmsley,
C Cohen, et al
PDF
Poster
Abstract
-
Effect
of Baseline Characteristics on Treatment Outcomes in ACTG 5142: A
Prospective, Randomized,
Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial
Treatment of HIV-1 Infection
S Riddler, R Haubrich, G DiRienzo, et al
Abstract
|
|
|
|
6th
IAS Conference
Conference
Archives
Main
New/Newsworthy